FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947029332> ?p ?o ?g. }

• W2947029332 endingPage "e15748" @default.
• W2947029332 startingPage "e15748" @default.
• W2947029332 abstract "e15748 Background: Pancreatic cancer is one of the world’s deadliest malignancies with an average 5-year survival rate of only 9%. Fortunately, immunotherapy is providing encouraging results for treatment of this historically resistant malignancy. Kiromic Biopharma is performing a phase I/II dendritic cell vaccine trial for progressive solid malignancies. We present here a notable response to metastatic pancreatic cancer. Methods: The patient is a 73-year-old male with the history of a locally advanced pancreatic cancer treated initially with gemcitabine, concurrent 5FU and radiation therapy, and consolidation 5FU, followed by surgical resection in 2009 . Although the patient did well exceeding typical survival curves, the patient’s cancer became metastatic, requiring multiple lines of chemotherapy including FOLFIRINOX, gemzar and abraxane, and most recently Onivyde and leucovorin/5FU in February - August, 2017 for progressive liver and lung metastases. The patient was then enrolled onto Kiromic Biopharma’s DC vaccination trial in March, 2018. Results: He subsequently received 6 ID autologous dendritic cell vaccinations over 12 weeks, demonstrating a tumor antigen specific immunogenic response by IFN-gamma immunoassay. Total tumor burden (TTB) prior to clinical trial enrollment at the sites of metastatic disease was 2,221mm2, and after completion of the DC vaccination protocol in May, 2018, the TTB increased to 4,466mm2 in June, 2018 (not considered to be pseudo-progression due to a corresponding increase in tumor biomarkers). The patient then received a repeat course of Onivyde and leucovorin/5FU on 8-3-18, completing that course of therapy on 9-14-18, with subsequent TTB decreasing to 2,986 mm2. Conclusions: The sequential combination of dendritic cell vaccine and chemotherapy resulted in a substantial response with a recession in metastatic tumor burden. A CT scan was obtained just 6 days after the 5 week course of Onivyde was completed, and given the optimal immunotherapy window after the DC vaccination, and the repeat of the same chemotherapy regimen, it is unlikely that chemotherapy alone led to such a rapid decrease in the TTB. Metastatic sites were likely populated by chemo resistant clones that survived the August 2017 administration of the Onivyde regimen. Thus, chemo alone would be unlikely to act so quickly. We hypothesize that there was synergistic activity between the DC immunotherapy and the Onivyde/5FU regimen, accounting for the decrease in TTB between May and September, 2018. Clinical trial information: NCT02705703." @default.
• W2947029332 created "2019-06-07" @default.
• W2947029332 creator A5004960695 @default.
• W2947029332 creator A5008320327 @default.
• W2947029332 creator A5022084686 @default.
• W2947029332 creator A5026658545 @default.
• W2947029332 creator A5043523278 @default.
• W2947029332 creator A5055996591 @default.
• W2947029332 date "2019-05-20" @default.
• W2947029332 modified "2023-10-17" @default.
• W2947029332 title "Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer." @default.
• W2947029332 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e15748" @default.
• W2947029332 hasPublicationYear "2019" @default.
• W2947029332 type Work @default.
• W2947029332 sameAs 2947029332 @default.
• W2947029332 citedByCount "2" @default.
• W2947029332 countsByYear W29470293322021 @default.
• W2947029332 countsByYear W29470293322023 @default.
• W2947029332 crossrefType "journal-article" @default.
• W2947029332 hasAuthorship W2947029332A5004960695 @default.
• W2947029332 hasAuthorship W2947029332A5008320327 @default.
• W2947029332 hasAuthorship W2947029332A5022084686 @default.
• W2947029332 hasAuthorship W2947029332A5026658545 @default.
• W2947029332 hasAuthorship W2947029332A5043523278 @default.
• W2947029332 hasAuthorship W2947029332A5055996591 @default.
• W2947029332 hasConcept C121608353 @default.
• W2947029332 hasConcept C126322002 @default.
• W2947029332 hasConcept C143998085 @default.
• W2947029332 hasConcept C203014093 @default.
• W2947029332 hasConcept C22070199 @default.
• W2947029332 hasConcept C2776256026 @default.
• W2947029332 hasConcept C2776694085 @default.
• W2947029332 hasConcept C2777701055 @default.
• W2947029332 hasConcept C2778822529 @default.
• W2947029332 hasConcept C2779399171 @default.
• W2947029332 hasConcept C2780210213 @default.
• W2947029332 hasConcept C2780258809 @default.
• W2947029332 hasConcept C71924100 @default.
• W2947029332 hasConceptScore W2947029332C121608353 @default.
• W2947029332 hasConceptScore W2947029332C126322002 @default.
• W2947029332 hasConceptScore W2947029332C143998085 @default.
• W2947029332 hasConceptScore W2947029332C203014093 @default.
• W2947029332 hasConceptScore W2947029332C22070199 @default.
• W2947029332 hasConceptScore W2947029332C2776256026 @default.
• W2947029332 hasConceptScore W2947029332C2776694085 @default.
• W2947029332 hasConceptScore W2947029332C2777701055 @default.
• W2947029332 hasConceptScore W2947029332C2778822529 @default.
• W2947029332 hasConceptScore W2947029332C2779399171 @default.
• W2947029332 hasConceptScore W2947029332C2780210213 @default.
• W2947029332 hasConceptScore W2947029332C2780258809 @default.
• W2947029332 hasConceptScore W2947029332C71924100 @default.
• W2947029332 hasIssue "15_suppl" @default.
• W2947029332 hasLocation W29470293321 @default.
• W2947029332 hasOpenAccess W2947029332 @default.
• W2947029332 hasPrimaryLocation W29470293321 @default.
• W2947029332 hasRelatedWork W1965851372 @default.
• W2947029332 hasRelatedWork W2094153719 @default.
• W2947029332 hasRelatedWork W2115579238 @default.
• W2947029332 hasRelatedWork W2126322332 @default.
• W2947029332 hasRelatedWork W2596055884 @default.
• W2947029332 hasRelatedWork W2885862304 @default.
• W2947029332 hasRelatedWork W3031244932 @default.
• W2947029332 hasRelatedWork W3031675857 @default.
• W2947029332 hasRelatedWork W4205828341 @default.
• W2947029332 hasRelatedWork W4281720666 @default.
• W2947029332 hasVolume "37" @default.
• W2947029332 isParatext "false" @default.
• W2947029332 isRetracted "false" @default.
• W2947029332 magId "2947029332" @default.
• W2947029332 workType "article" @default.